ADRIATIC: patterns of disease progression with durvalumab in LS-SCLC
Suresh Senan, MRCP, FRCR, PhD, Amsterdam University Medical Centers, Amsterdam, Netherlands, discusses findings from the ADRIATIC study (NCT03703297) of durvalumab consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC). Results suggest durvalumab consolidation therapy reduced extrathoracic metastases and prolonged time to progression or death compared to placebo. This interview took place at the European Lung Cancer Congress (ELCC) 2025 in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
